Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA.

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

ADMA Biologics

Corcept Therapeutics

Exelixis

Ligand Pharmaceuticals

The top five biotech stocks today have several commonalities. Among them are strong ratings.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Larimar Therapeutics Inc

Madrigal Pharmaceuticals

Theravance Biopharma

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Richard Daly - President and Chief Executive Officer Michael Kalb - Chief Financial Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical & Regulatory Officer Conference Call Participants Joon Lee - Truist Securities Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citi Investment Research Operator Thank you for standing by. My name is Kris and I will be your conference operator today.

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript

Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.24 per share a year ago.

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates

Reports Q3 2024 Total Revenues of $ 128.7 Million, Representing a 25.3 % YoY Increase

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

Stevanato Group SpA

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

CPRX vs. STVN: Which Stock Is the Better Value Option?

Atour Lifestyle Holdings Ltd

Limbach Holdings

Vertiv Holdings Co

Pick these four top-ranked stocks, VRT, LMB, ATAT and CPRX, with solid net profit margins to enhance your portfolio returns.

Pick These 4 Solid Net Profit Margin Stocks to Boost Portfolio Return

The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?

CPRX or STVN: Which Is the Better Value Stock Right Now?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Catalyst (CPRX) a Good Fit for 'Trend Investing'

Allegiant Travel Company

America Movil SAB de CV

Barrick Gold

Add value to your portfolio with high earnings yield stocks like GOLD, CPRX, ALGT and AMX amid market uncertainty.

Unlock Your Portfolio Value With These 4 High Earnings Yield Stocks

CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene.

News for Catalyst Pharmaceuticals Stock (CPRX)